A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating

Recruiting

99 years or below

All

Phase 2

5 participants needed

1 Location

Brief description of study

A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population is patients with NASH and F3 fibrosis, between the ages of 18-75.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: liver fibrosis
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 833117

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Brief description of study

Eligibility of study

Find a site

Interested in the study